BI 1569912 vs Blixeprodil

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

BI 1569912

Developed by Boehringer Ingelheim

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT06280235 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 243 participants, using the clinical MADRS depression score as its primary endpoint. However, the prespecified primary dose-response analysis was not statistically significant, so the trial provides well-controlled but inconclusive evidence of benefit.

Reported efficacy

Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) (missed)

Result source: NCT06558344

Blixeprodil

Developed by Gilgamesh Pharma

Phase 2 in Major Depressive Disordersmall molecule
Weak signal

NCT06309277 · Phase 2 · completed

This two-part, randomized, quadruple-blind, placebo-controlled Phase 2a study gave single and multiple oral doses of GM-1020 (blixeprodil) or placebo to 46 patients with major depressive disorder. The only registered primary outcome is the incidence of treatment-emergent adverse events, which has no formal efficacy test, so there is no met or missed result. Antidepressant response was a preliminary, non-primary aim. Source: CT.gov posted results. Its registered primary outcome on ClinicalTrials.gov is "Incidence of Treatment Emergent Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Reported efficacy

Incidence of Treatment Emergent Adverse Events (Baseline, Day 29): Primary outcome, incidence of treatment-emergent adverse events to Day 29 (no formal efficacy test): Part A, 23 participants on placebo and 43 on GM-1020 140 mg with at least one TEAE (CT.gov posted results). (not_applicable)

Result source: NCT06309277

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBI 1569912Blixeprodil
MADRS, change (acute)-12.3 vs -12−0.3 vs placebo20 mg · wk 6 · n 74NCT06280235
10 other results
  • -10 vs -10.3 20 mg · wk 6 · n 66 · Phase 2 · primary NCT06558344
  • -19.9 vs -19.3 20 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -11.9 vs -12 10 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -10.6 vs -10.3 10 mg · wk 6 · n 36 · Phase 2 · primary NCT06558344
  • -16.8 vs -19.3 5 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -7.8 vs -12 5 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -13.6 vs -10.3 5 mg · wk 6 · n 30 · Phase 2 · primary NCT06558344
  • -5.7 vs -6.4 20 mg · wk 1.142857 · n 74 · Phase 2 · secondary NCT06280235
  • -5.9 vs -6.4 10 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
  • -5.2 vs -6.4 5 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
-10.5 vs -5.4−5.1 vs placebo140 mg · wk 1.14 · n 24NCT06309277
1 other result
  • -12.1 vs -5.8 140 mg · wk 0.14 · n 25 · Phase 2 · secondary NCT06309277
CGI-S, change (acute)—Not reported—Not reported
MADRS response34.8% vs 33.8%+1 vs placebo20 mg · wk 6 · n 66NCT06280235
5 other results
  • 15.5% vs 11.3% 20 mg · wk 1.142857 · n 71 · Phase 2 · secondary NCT06280235
  • 31.4% vs 33.8% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 10 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
  • 20.6% vs 33.8% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 5 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
—Not reported
MADRS remission21.2% vs 19.7%+1.5 vs placebo20 mg · wk 6 · n 66NCT06280235
2 other results
  • 25.7% vs 19.7% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 8.8% vs 19.7% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

BI 1569912
-12.3 vs -12−0.3 vs placebo20 mg · wk 6 · n 74NCT06280235
10 other results
  • -10 vs -10.3 20 mg · wk 6 · n 66 · Phase 2 · primary NCT06558344
  • -19.9 vs -19.3 20 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -11.9 vs -12 10 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -10.6 vs -10.3 10 mg · wk 6 · n 36 · Phase 2 · primary NCT06558344
  • -16.8 vs -19.3 5 mg · wk 1 · n 20 · Phase 1 · primary NCT04937829
  • -7.8 vs -12 5 mg · wk 6 · n 38 · Phase 2 · primary NCT06280235
  • -13.6 vs -10.3 5 mg · wk 6 · n 30 · Phase 2 · primary NCT06558344
  • -5.7 vs -6.4 20 mg · wk 1.142857 · n 74 · Phase 2 · secondary NCT06280235
  • -5.9 vs -6.4 10 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
  • -5.2 vs -6.4 5 mg · wk 1.142857 · n 38 · Phase 2 · secondary NCT06280235
Blixeprodil
-10.5 vs -5.4−5.1 vs placebo140 mg · wk 1.14 · n 24NCT06309277
1 other result
  • -12.1 vs -5.8 140 mg · wk 0.14 · n 25 · Phase 2 · secondary NCT06309277

CGI-S, change (acute)

BI 1569912
—Not reported
Blixeprodil
—Not reported

MADRS response

BI 1569912
34.8% vs 33.8%+1 vs placebo20 mg · wk 6 · n 66NCT06280235
5 other results
  • 15.5% vs 11.3% 20 mg · wk 1.142857 · n 71 · Phase 2 · secondary NCT06280235
  • 31.4% vs 33.8% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 10 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
  • 20.6% vs 33.8% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
  • 11.1% vs 11.3% 5 mg · wk 1.142857 · n 36 · Phase 2 · secondary NCT06280235
Blixeprodil
—Not reported

MADRS remission

BI 1569912
21.2% vs 19.7%+1.5 vs placebo20 mg · wk 6 · n 66NCT06280235
2 other results
  • 25.7% vs 19.7% 10 mg · wk 6 · n 35 · Phase 2 · secondary NCT06280235
  • 8.8% vs 19.7% 5 mg · wk 6 · n 34 · Phase 2 · secondary NCT06280235
Blixeprodil
—Not reported

Relapse (% of patients)

BI 1569912
—Not reported
Blixeprodil
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. BI 1569912: 4 of 4 rows · Blixeprodil: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBI 1569912Blixeprodil
Dropout rate
9.6%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
7.3%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
12.5%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
9.6%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
14.6%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
17.1%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5%20 mg
NCT04937829 · Phase 1
15%5 mg
NCT04937829 · Phase 1
—210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Discontinued due to AEs
2.4%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
4.9%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2.7%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
4.9%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—20 mg
NCT04937829 · Phase 1
—5 mg
NCT04937829 · Phase 1
—210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
—140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Serious AEs
1.2%20 mga
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
2.4%10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%20 mg
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
2.4%10 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%5 mg
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%20 mg
NCT04937829 · Phase 1
0%5 mg
NCT04937829 · Phase 1
0%210 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
0%140 mg
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Most frequent reported AEs
20 mga
dizziness 8.4% (placebo 2.5%)
headache 8.4% (placebo 6.3%)
nasopharyngitis 4.8% (placebo 3.8%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 7 more results
10 mg
headache 4.9% (placebo 6.3%)
upper respiratory tract infection 2.4% (placebo 6.3%)
dizziness 0% (placebo 2.5%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5 mg
headache 7.5% (placebo 6.3%)
nasopharyngitis 7.5% (placebo 3.8%)
upper respiratory tract infection 5% (placebo 6.3%)
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20 mg
headache 12.3% (placebo 7.9%)
nasopharyngitis 8.2% (placebo 3.9%)
diarrhoea 2.7% (placebo 1.3%)
NCT06558344 · Phase 2 · Major Depressive Disorder · phase 2
10 mg
headache 9.8% (placebo 7.9%)
diarrhoea 4.9% (placebo 1.3%)
nasopharyngitis 4.9% (placebo 3.9%)
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
5 mg
headache 14.3% (placebo 7.9%)
diarrhoea 5.7% (placebo 1.3%)
upper respiratory tract infection 5.7% (placebo 1.3%)
NCT06558344 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20 mg
decreased appetite 5% (placebo 5.3%)
blood pressure increased 0% (placebo 0%)
constipation 0% (placebo 0%)
NCT04937829 · Phase 1
5 mg
blood pressure increased 10% (placebo 0%)
constipation 10% (placebo 0%)
headache 5% (placebo 5.3%)
NCT04937829 · Phase 1
210 mg
time perception altered 63.2% (placebo 0%)
euphoric mood 57.9% (placebo 0%)
hallucination, visual 57.9% (placebo 0%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
140 mg
dizziness 46.5% (placebo 4.5%)
euphoric mood 44.2% (placebo 0%)
headache 37.2% (placebo 18.2%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
140 mg
euphoric mood 61.1% (placebo 0%)
dizziness 50% (placebo 4.5%)
headache 50% (placebo 18.2%)
NCT06309277 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

BI 1569912

MADRS 15.5% (n=71) vs 11.3% (n=71) placebo @ 1.142857wk20 mg
responder rate · % of participants
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 5 more results
34.8% (n=66) vs 33.8% (n=71) placebo @ 6wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
11.1% (n=36) vs 11.3% (n=71) placebo @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
31.4% (n=35) vs 33.8% (n=71) placebo @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
11.1% (n=36) vs 11.3% (n=71) placebo @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20.6% (n=34) vs 33.8% (n=71) placebo @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
MADRS Remission 21.2% (n=66) vs 19.7% (n=71) placebo @ 6wk20 mg
responder rate · % of participants
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
25.7% (n=35) vs 19.7% (n=71) placebo @ 6wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8.8% (n=34) vs 19.7% (n=71) placebo @ 6wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
SMDDS -7.1 vs -7.6 placebo score @ 1.142857wk20 mg
absolute change · score
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 5 more results
-11.1 vs -10.4 placebo score @ 4wk20 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-6.5 vs -7.6 placebo score @ 1.142857wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.8 vs -10.4 placebo score @ 4wk10 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-7.4 vs -7.6 placebo score @ 1.142857wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.3 vs -10.4 placebo score @ 4wk5 mg
NCT06280235 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BI 1569912's landscape · Blixeprodil's landscape